



Cordlife Group Limited

FY2025 Annual General Meeting

Regional Contribution · Singapore Operations

27 April 2026



Disclaimer

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Cordlife Group Limited ("Cordlife") in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any investment decision, contract or commitment whatsoever in this or any jurisdiction. This presentation may contain forward-looking statements that involve assumptions, risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. You are cautioned not to place undue reliance on these forward-looking statements, if any, which are based on the current view of management on future events. The information contained in this presentation has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Neither Cordlife or any of its affiliates, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. The past performance of Cordlife is not indicative future performance. The value of shares in Cordlife ("Shares") and the income derived from them may fall as well as rise. Shares are not obligations of, deposits in, or guaranteed by, Cordlife or any of its affiliates. An investment in Shares is subject to investment risks, including the possible loss of the principal amount invested.

AGENDA

Today's Meeting



1

FY25 Strategic Overview

Recovery and Regional Growth



2

FY25 Financial Performance

Key Highlights and Metrics



3

Revenue & Profitability

Analysis and Margin Trends



4

Operational Milestones

Process Enhancements & Governance



5

Strategic Outlook

Path to Sustainable Value



6

Tapping Growth Potential

Cord Blood Market Opportunities



Regional Contribution, Singapore Operations

Regional Strength

Overseas Market Dominance:

Overseas markets contributed **76% of Group revenue** in FY2025. Hong Kong continues to lead regional performance.

Infrastructure Investment:

Other regional markets are actively investing in infrastructure to tap significant long-term growth potential.

Singapore Operations

Governance & Leadership:

Leadership is focused on rigorous measures to strengthen processes, governance, and compliance standards.

Licensing Milestone:

Strategic improvements paving the way for renewals of cord blood and human tissue banking licenses in **2026**.

Key Financial Metrics




□ Revenue increased year-on-year, supported by operational recovery and reduced revenue reversals in FY2024.

¹: Includes cash and cash equivalents, fixed deposits, short-term investments less interest-bearing borrowings (current and non-current)

FY25 Revenue, Gross Profit and Gross Margin


FY2025 REVENUE

S\$ mil



FY2025 GROSS PROFIT/GROSS PROFIT MARGIN


S\$ mil



■ Gross profit ■ GPM

FY2025 PERCENTAGE OF REVENUE (%)

- Singapore
- Hong Kong
- India
- Malaysia
- Philippines
- Others



Strengthening Governance and Enhancing Customer Assurance



Process & Governance Enhancements

Implemented 24/7 remote monitoring systems for Singapore operations.

Hired experienced personnel to strengthen technical leadership.

Elevated training and competency standards across the Group.



Customer Assurance Initiatives

Rolled out enhanced service packages with extended storage terms.

Expanded warranty and financial coverage for peace of mind.

Direct engagement programs to address customer concerns.



Regional Growth & Outreach

Overseas operations stepped up partnerships with leading hospitals.

Increased social media engagement with prospective customers.

Infrastructure investments in regional markets to tap growth potential.



Path to Sustainable Value Creation



Regional Expansion

Overseas markets, e.g. HK, Philippines, India and Malaysia will remain key pillars of growth and innovation.



Striving towards Operational Excellence

Ongoing stabilisation of Singapore operations to support sustainable growth and restore trust.



Exploring Product Expansion

Potential new health-related offerings catering to anti-aging skincare treatment, subject to regulatory approvals and further evaluation.



Cordlife Singapore



Cordlife Hong Kong



HealthBaby



Cordlife India



Cordlife Philippines



Cordlife Indonesia



StemLife Malaysia

Southeast Asia's Cord Blood Market Opportunity



Southeast Asia's cord blood market projected to grow at 16.79% CAGR from 2025 to 2032 ¹



Rising adoption of stem cell therapies and preventive healthcare



Growing prevalence of chronic and genetic disorders driving demand



Building regional stem cell ecosystem through partnerships and education



Continuous facility upgrades to enhance efficiency and competitiveness

¹ Credence Research <https://www.credenceresearch.com/report/south-east-asia-umbilical-cord-blood-market>

Thank You...

We appreciate your continued support and
confidence in Cordlife Group Limited.

Cordlife Group Limited

Empowering families through stem
cell banking

FY2025 AGM

27 April 2026